Minerva Neurosciences, Inc.
NERVHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. At a $208.7M market cap, Minerva Neurosciences, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Market Cap
$208.7M
Beta
-0.18
P/E (TTM)
—
P/E (Fwd)
-9.33
EPS (TTM)
$-37.96
EPS (Fwd)
$-0.48
ROE
—
ROA
-27.5%
Cash
$78.1M
Total Debt
$60.0M
Free CF
-$5.5M
52W Change
126.3%
Annual Financials
Cash vs Debt
Where NERV stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NERV finished 24.58% below its 150-day moving average ($5.33) and 17.45% below its 200-day moving average ($4.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NERV overbought or oversold?
At the July 15, 2026 close, NERV's RSI(14) was 45.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Minerva Neurosciences, Inc. holds $78.1M in cash against $60.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$5.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
With a beta below 0.7, Minerva Neurosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Minerva Neurosciences, Inc.'s trajectory.